drugset / Trial / NCT03175120

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

NCT03175120

Phase 3 Completed 453 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

Timeline

Start
2017-05-26
Primary completion
2019-03-05
Completion
2019-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin degludec/liraglutide Unknown Subcutaneous
Subject insulin degludec Protein / enzyme biologic Subcutaneous